Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy...

[cafead]

via

• Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treating Nectin-4-driven cancers, starting with metastatic urothelial cancer (mUC)
• Updated BT8009 clinical data continue to support promising response and differentiated safety profile in mUC as well as emerging clinical activity in additional tumor types beyond bladder
• EphA2 portfolio led by BT5528 could be the first to address a historically undruggable target widely expressed in many cancers

article source